An important part of current oncologic practice is the ability to assay cancers for biological features to guide therapeutic choices.
1 Cancer biomarkers are traditionally based on in vitro tissue assays.
2 Advances in molecular biology and laboratory-based methods have increased the ability to measure cancer biology, including genomics, gene expression, and protein expression.
3- 6 Similarly, advances in both technology and cancer science now provide the ability to perform noninvasive cancer assays, including molecular imaging.
7 The Society of Nuclear Medicine and Molecular Imaging defines molecular imaging as “the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems.”
8[p18N] Thus far, clinical molecular imaging has been largely radionuclide based in the form of positron emission tomography (PET) or single-photon emission computed tomography. Ongoing work in optical, photoacoustic, ultrasonographic, and hyperpolarized magnetic resonance imaging and spectroscopy offers capabilities highly complementary to radioisotope imaging.
9,10